Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Holding ARWR?
Track your performance easily
Earnings Data
Report Date
Feb 05, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-$0.41Last Year’s EPS
-$1.24Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 26, 2024
|% Change Since: -7.60%
|Next Earnings Date:Feb 05, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a strong focus on strategic growth and clinical advancements for Arrowhead, particularly through plozasiran's promising results and pipeline expansion. However, financial challenges remain with increased losses and R&D expenses, balanced by strategic financing efforts.Company Guidance
During the Arrowhead Pharmaceuticals Q3 2024 earnings call, the company provided guidance on its strategic initiatives and financial outlook. Arrowhead is focused on its 2025 initiative, which aims to expand its pipeline to at least 20 clinical stage or marketed products by next year. A significant part of this plan involves the launch of plozasiran, which is expected next year, pending approval for familial chylomicronemia syndrome (FCS). The company reported a net loss of $170.8 million for the quarter, with no revenue recorded, and total operating expenses rising to $176.1 million, attributed to increased R&D activities. Arrowhead also announced a $500 million senior secured credit facility with Sixth Street to bolster its balance sheet, with $400 million available immediately and $100 million subject to mutual agreement. This facility is structured to enable long-term, non-dilutive funding, aligning with the company's strategy to bridge its financial needs until commercial revenue from plozasiran becomes substantial.Plozasiran Clinical Advancements
Plozasiran has shown promising results in various trials, including the Phase III PALISADE study, and has potential for multiple indications such as FCS, SHTG, and mixed hyperlipidemia. The drug achieved up to 80% reduction in triglycerides in the PALISADE study.
Strategic Financing
Arrowhead secured a $500 million senior secured credit facility from Sixth Street, enhancing liquidity for global commercial launches and clinical trials.
Ongoing Pipeline Expansion
Arrowhead's pipeline includes multiple promising candidates, such as ARO-RAGE for asthma and ARO-INHBE for obesity, with plans to file CTAs for new candidates by the end of the year.
Positive Commercial Preparation
Arrowhead is building a robust commercial infrastructure for the launch of plozasiran, with a focus on patient support and market readiness.
Milestone Payment
Arrowhead received a $50 million milestone payment from Royalty Pharma, strengthening its financial position.
---
ARWR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARWR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 26, 2024 | $21.05 | $26.15 | +24.23% |
| Aug 08, 2024 | $25.85 | $23.41 | -9.44% |
| May 09, 2024 | $24.72 | $22.08 | -10.68% |
| Feb 06, 2024 | $33.20 | $31.65 | -4.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arrowhead Pharmaceuticals (ARWR) report earnings?
Arrowhead Pharmaceuticals (ARWR) is schdueled to report earning on Feb 05, 2025, TBA Not Confirmed.
What is Arrowhead Pharmaceuticals (ARWR) earnings time?
Arrowhead Pharmaceuticals (ARWR) earnings time is at Feb 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARWR EPS forecast?
ARWR EPS forecast for the fiscal quarter 2025 (Q1) is -$0.41.
---